Introduction
Burst release in PLGA formulations is one of the most clinically consequential — and analytically challenging — phenomena in controlled-release drug delivery. When a PLGA microsphere, implant, or in situ forming depot is administered, the immediate shedding of a large fraction of the drug payload in the first few hours can compromise the entire therapeutic objective of the formulation. For contract research organizations (CROs) and pharmaceutical developers working on long-acting injectables (LAIs), understanding and controlling burst release is not optional — it is a regulatory expectation and a patient safety imperative.
At ResolveMass Laboratories Inc., we routinely characterize and develop PLGA-based drug delivery systems, including complex microsphere formulations, solid cylindrical implants, and in situ forming depots. This article draws on our hands-on formulation and analytical experience to explain what causes burst release in PLGA formulations, what the downstream consequences are, and — critically — how to mitigate it during development.
Summary:
- Burst release in PLGA formulations refers to a rapid, uncontrolled release of drug substance within the first 24–72 hours of implant or microsphere administration — often representing 10–40% of the total drug load.
- The primary causes include surface-adsorbed or loosely entrapped drug, polymer–drug incompatibility, non-uniform encapsulation, and accelerated early-phase water ingress.
- Uncontrolled burst release can lead to dose dumping, systemic toxicity, shortened depot duration, and regulatory non-compliance under FDA and Health Canada guidelines.
- Mitigation strategies span formulation design (polymer molecular weight, end-group chemistry, drug loading optimization), process controls (emulsification parameters, solvent selection), and surface modification approaches.
- ResolveMass Laboratories Inc. offers end-to-end analytical and formulation development services to characterize, understand, and control burst release in PLGA-based long-acting injectable (LAI) and implant systems.
1: What Is Burst Release in PLGA Formulations?
Burst release in PLGA formulations is defined as the rapid, disproportionate release of a drug substance within the first 24–72 hours of implantation or injection, well before the intended sustained-release phase begins. In quantitative terms, a burst is typically identified when ≥10–40% of the encapsulated drug is released within the initial timeframe, though the threshold varies by product and regulatory context.
This phenomenon is distinct from the intended biphasic or triphasic release profile that PLGA matrices are designed to deliver. The classic PLGA release profile consists of:
- Phase 1 (Burst phase): Initial rapid release (hours to days)
- Phase 2 (Lag phase): Diffusion-controlled slow release
- Phase 3 (Erosion phase): Bulk hydrolysis and accelerated release as polymer degrades
The challenge is that in poorly optimized formulations, Phase 1 is exaggerated — producing an uncontrolled dose spike that is pharmacologically equivalent to an immediate-release administration event.
2: Root Causes of Burst Release in PLGA-Based Drug Delivery Systems
1. Surface-Localized and Loosely Entrapped Drug
The most direct cause of burst release is the presence of drug molecules at or near the microsphere or implant surface. During the emulsification–solvent evaporation process, drug molecules with higher hydrophilicity tend to migrate toward the outer aqueous phase, accumulating in the outermost polymer shell. Upon contact with biological fluid, this surface reservoir dissolves instantly.
Key contributing factors include:
- High drug hydrophilicity (logP < 1)
- Rapid solvent evaporation during microencapsulation
- Inadequate homogenization, leaving unevenly distributed drug clusters near the surface
- Drug precipitation at the oil–water interface during double-emulsion (w/o/w) preparation
2. Polymer–Drug Incompatibility and Phase Separation
When the drug and PLGA polymer are thermodynamically incompatible, phase separation occurs during solvent removal. The drug-rich phase migrates to the particle surface or forms discrete pockets within the matrix. These drug-rich microdomains are rapidly accessed by water upon administration, releasing large amounts before the polymer begins to degrade.
This is especially pronounced with:
- Peptide and protein APIs that have poor solubility in organic solvents
- Small molecule drugs with strong hydrogen-bonding capability that repels PLGA chains
- Formulations using low-molecular-weight PLGA grades with faster water uptake kinetics
3. High Porosity and Non-Uniform Internal Morphology
Porosity within PLGA microparticles is a double-edged sword. While some porosity facilitates sustained diffusion, excessive or interconnected porosity — particularly near the particle surface — creates channels through which drug can rapidly leach out before polymer erosion begins.
Morphological contributors include:
| Morphological Feature | Effect on Burst Release |
|---|---|
| Open surface pores | Rapid aqueous infiltration and drug dissolution |
| Drug aggregation near pores | Localized high-concentration dissolution |
| Incomplete polymer shell formation | Loss of barrier function |
| High internal void fraction | Increased available diffusion pathways |
| Interconnected pore networks | Accelerated early-phase water ingress |
Scanning electron microscopy (SEM) and micro-CT are standard tools at ResolveMass for evaluating these morphological parameters and correlating them directly with burst release behavior.
4. Polymer Molecular Weight and End-Group Chemistry
The molecular weight (MW) and end-group chemistry of PLGA have a profound influence on burst release. Acid-terminated (uncapped) PLGA grades are more hydrophilic due to free carboxylic acid end groups, which accelerate water uptake and autocatalytic degradation — both of which drive higher burst.
| PLGA Parameter | Impact on Burst Release |
|---|---|
| Low MW (< 20 kDa) | Higher hydrophilicity, faster degradation → higher burst |
| High MW (> 75 kDa) | Denser matrix, slower water ingress → lower burst |
| Acid end-capped (free –COOH) | Autocatalytic acidification → higher burst |
| Ester end-capped (–COOR) | Slower degradation initiation → lower burst |
| High LA:GA ratio (e.g., 85:15) | More hydrophobic → lower burst |
| Low LA:GA ratio (e.g., 50:50) | Faster degradation, more hydrophilic → higher burst |
5. Drug Loading Level
There is a well-documented direct relationship between drug loading and burst release. As drug loading increases beyond the optimal encapsulation efficiency threshold, drug–polymer interactions weaken and drug molecules that cannot be fully entrapped within the polymer matrix reside near the surface. This excess drug is particularly susceptible to rapid dissolution.
For most PLGA microsphere systems, drug loading above 20–30% w/w carries elevated burst risk, though this threshold is highly API- and formulation-specific.
6. Residual Solvent and Manufacturing Process Variables
The choice of organic solvent (e.g., dichloromethane, ethyl acetate, acetone) and the rate of solvent evaporation directly impact the final internal morphology and surface characteristics of PLGA particles. Faster evaporation rates create a denser outer shell, which can limit burst — but also trap residual solvent that disrupts matrix integrity upon removal.
Critical process variables affecting burst release include:
- Homogenization speed and time during primary and secondary emulsion formation
- Solvent evaporation rate (temperature, stirring speed)
- Hardening medium composition and temperature
- Lyophilization cycle (for microsphere powders)
3: Consequences of Uncontrolled Burst Release
Clinical and Safety Implications
The clinical consequences of an excessive burst depend strongly on the API’s therapeutic index. For potent drugs — including opioid antagonists (naltrexone), antipsychotics (risperidone, aripiprazole lauroxil), oncology agents (leuprolide, goserelin), or peptide hormones — an uncontrolled dose spike can result in:
- Dose dumping: Plasma concentrations exceeding the maximum safe threshold
- Adverse events and toxicity: Particularly for narrow therapeutic index drugs
- Shortened depot duration: Because drug consumed in burst is unavailable for sustained delivery
- Loss of therapeutic efficacy toward the end of the dosing interval
Regulatory Consequences
From a regulatory perspective, burst release is evaluated as part of the in vitro release testing (IVRT) package. Both the FDA and Health Canada expect:
- A well-characterized and reproducible in vitro release profile using validated methods (e.g., USP Apparatus 4, membrane diffusion, or dialysis-based methods)
- Mechanistic justification for any observed burst component
- Correlation between burst release parameters and clinical PK data (IVIVC) for injectable depots
- Process controls demonstrating burst variability is within specified limits across batches
Failure to characterize and control burst release in PLGA formulations during development will result in regulatory scrutiny during NDA, ANDA (for generic injectables), or 505(b)(2) submissions.
4: How to Mitigate Burst Release in PLGA Formulations
Formulation-Level Strategies
Polymer Selection: Selecting higher-molecular-weight, ester end-capped PLGA with a higher LA:GA ratio reduces water uptake and slows initial degradation, blunting the burst phase. Blending PLGA grades of different MW and end-group chemistry allows fine-tuning of the release profile.
Drug Loading Optimization: Keeping drug loading within the encapsulation efficiency sweet spot — typically 10–25% for most microsphere formulations — reduces surface excess drug. Solubility parameter matching between API and polymer reduces phase separation risk.
Excipient Co-encapsulation: Hydrophobic excipients such as magnesium stearate, lecithin, or fatty acid esters can coat drug particles during encapsulation, creating a secondary diffusion barrier that blunts the initial burst. PEGylation of the PLGA surface or use of PLA-PEG block copolymers has also shown efficacy in reducing burst in microsphere formulations.
Surface Coating: Post-formation coating with dilute PLGA solution, albumin, or polylysine can seal surface pores and reduce the immediately accessible drug reservoir.
Process-Level Strategies
| Mitigation Strategy | Mechanism | Typical Effect on Burst |
|---|---|---|
| Slower solvent evaporation | Denser, more uniform shell formation | Reduces burst |
| Higher MW PLGA | Slows water diffusion into matrix | Reduces burst |
| Ester-capped PLGA | Suppresses autocatalytic degradation | Reduces burst |
| Lower drug loading | Reduces surface drug excess | Reduces burst |
| Hydrophobic excipients | Secondary diffusion barrier | Reduces burst |
| Optimized homogenization | More uniform particle morphology | Reduces burst |
| Solvent selection (EtAc vs DCM) | Controls extraction kinetics | Formulation-specific |
| Surface washing/extraction step | Removes surface-adsorbed drug | Reduces burst |
Analytical Characterization to Inform Mitigation
Effective mitigation is impossible without robust characterization. At ResolveMass Laboratories, our burst release mitigation programs integrate multiple analytical techniques:
- In vitro release testing (IVRT) using USP Apparatus 4 (flow-through cell) or membrane-based systems to capture early-phase kinetics with high temporal resolution
- SEM and micro-CT for morphological characterization of porosity and surface drug distribution
- DSC and XRPD to assess drug–polymer physical state and detect amorphous drug clustering at the surface
- GPC/SEC to confirm PLGA molecular weight and batch-to-batch polymer consistency
- LC-MS/MS for high-sensitivity quantification of drug released in early time points (hours 1–24)
- Confocal microscopy / fluorescence imaging for direct visualization of drug distribution within microsphere cross-sections
This integrated analytical approach allows ResolveMass scientists to pinpoint the mechanistic origin of burst release in any given PLGA system and recommend targeted, evidence-based mitigation strategies.
5: Burst Release Characterization: Regulatory and Method Considerations
FDA and Health Canada Expectations
The FDA’s guidance on extended-release injectable suspensions and implants (including 2014 draft guidance on dissolution testing for parenteral drug products) explicitly addresses in vitro release method development for PLGA formulations. Key expectations include:
- Sink conditions must be maintained throughout the test, including during the burst phase
- Sampling frequency during burst phase (0, 1, 4, 8, 24, 48 h) must be sufficient to define the initial release kinetics
- Method discriminating ability — the IVRT method must distinguish between formulations with different burst profiles
- Correlation to in vivo PK data is expected for NDA/ANDA submissions involving depot injectable systems
Health Canada’s guidance similarly aligns with ICH Q6A and Q6B standards for physical and chemical characterization, with emphasis on demonstrating process and analytical control over the entire release profile — burst phase included.
Key Performance Indicators for Burst Release Assessment
- Burst release fraction (% released at t = 1h, 4h, 24h)
- Time to peak burst release concentration
- Ratio of burst to steady-state release rate
- Intra- and inter-batch variability of burst fraction
- Correlation coefficient (R²) in IVIVC analysis
Conclusion:
Burst release in PLGA formulations remains one of the most technically and regulatory complex challenges in long-acting injectable drug development. Its causes span polymer chemistry, formulation design, manufacturing process variables, and API physicochemical properties — which is precisely why a systematic, analytically rigorous approach is essential from early development through process scale-up.
At ResolveMass Laboratories Inc., we bring deep expertise in PLGA-based formulation science, validated IVRT method development, and polymer characterization to support pharmaceutical developers in understanding and controlling burst release in PLGA formulations. Whether you are developing a novel LAI product, conducting comparative characterization studies, or preparing regulatory submissions, our team is equipped to deliver the data and mechanistic insight you need.
Frequently Asked Questions:
Burst release in PLGA microspheres is primarily caused by surface-associated drug, high particle porosity, polymer–drug incompatibility, and manufacturing process variables. Drug molecules located near the particle surface dissolve rapidly upon contact with biological fluids. Inadequate encapsulation efficiency and uneven drug distribution can further increase burst release. Polymer properties such as molecular weight and end-group chemistry also influence initial drug release. Multiple factors usually contribute simultaneously to the observed burst effect.
Not necessarily. In some formulations, a controlled initial burst can help achieve therapeutic drug levels quickly before sustained release takes over. This can be particularly useful when an immediate pharmacological effect is desired. However, excessive burst release can lead to safety concerns and compromise long-term drug delivery. The ideal burst profile depends on the drug, indication, and intended release characteristics. Careful formulation design is required to balance initial and sustained release.
Higher drug loading generally increases the risk of burst release because excess drug may not be fully encapsulated within the polymer matrix. Drug molecules can accumulate near the particle surface or within pores, making them readily available for rapid dissolution. Increased drug loading can also alter particle morphology and create additional diffusion pathways. As a result, formulations with very high drug content often exhibit larger initial release phases. Optimal drug loading must balance efficacy and release control.
PLGA molecular weight affects polymer density, water uptake, and degradation behavior. Lower molecular weight PLGA absorbs water more readily and degrades faster, often resulting in higher burst release. Higher molecular weight PLGA forms denser matrices that slow water penetration and drug diffusion. Consequently, formulations using high molecular weight polymers generally show lower initial release. Polymer molecular weight is one of the most important variables in release profile optimization.
Porosity determines how easily water can enter the particle and access encapsulated drug. Highly porous particles contain channels and voids that facilitate rapid fluid penetration and drug diffusion. Open surface pores are especially problematic because they provide direct pathways for early drug release. Excessive porosity often results from manufacturing conditions or solvent removal processes. Reducing uncontrolled porosity can significantly decrease burst release.
Reference
- Allison SD. Analysis of initial burst in PLGA microparticles. Expert opinion on drug delivery. 2008 Jun 1;5(6):615-28.https://www.tandfonline.com/doi/abs/10.1517/17425247.5.6.615
- Bakhrushina EO, Sakharova PS, Konogorova PD, Pyzhov VS, Kosenkova SI, Bardakov AI, Zubareva IM, Krasnyuk II, Krasnyuk Jr II. Burst release from in situ forming PLGA-based implants: 12 effectors and ways of correction. Pharmaceutics. 2024 Jan 16;16(1):115.https://www.mdpi.com/1999-4923/16/1/115
- Yoo J, Won YY. Phenomenology of the initial burst release of drugs from PLGA microparticles. ACS Biomaterials Science & Engineering. 2020 Oct 9;6(11):6053-62.https://pubs.acs.org/doi/abs/10.1021/acsbiomaterials.0c01228
- Bhattacharjee S. Understanding the burst release phenomenon: Toward designing effective nanoparticulate drug-delivery systems. Therapeutic Delivery. 2021 Jan 1;12(1):21-36.https://www.tandfonline.com/doi/abs/10.4155/tde-2020-0099
- de Azevedo CR, von Stosch M, Costa MS, Ramos AM, Cardoso MM, Danhier F, Préat V, Oliveira R. Modeling of the burst release from PLGA micro-and nanoparticles as function of physicochemical parameters and formulation characteristics. International journal of pharmaceutics. 2017 Oct 30;532(1):229-40.https://www.sciencedirect.com/science/article/pii/S0378517317308359
About the Author
